Surge of Miller Fisher variant and Guillain-Barré syndrome in two downtown Los Angeles community teaching hospitals

Michael C. Yang1 | Antonio Liu2,3

1Department of Internal Medicine, Adventist Health White Memorial, Los Angeles, CA
2Department of Neurology, Adventist Health White Memorial, Los Angeles, CA
3Department of Neurology, California Hospital Medical Center, Los Angeles, CA

Correspondence
Antonio Liu, Department of Neurology, Adventist Health White Memorial, Los Angeles, CA. Email: liuak@ah.org

Abstract
Guillain-Barré syndrome (GBS) and Miller Fisher variant (MFv) cases spiked three-fold in Los Angeles, with a high proportion of MFv cases. MFv is underdiagnosed when accompanying neurological symptoms are mild. This report emphasizes the seasonality of GBS and its relation to ganglioside antibodies.

Keywords
ganglioside antibody tests, Guillain-Barré syndrome, Los Angeles, Miller Fisher syndrome, Miller Fisher variant, ophthalmoplegia

1 INTRODUCTION

Guillain-Barré syndrome (GBS) is a group of acute polyneuropathies that occurs after an antecedent illness that triggers antibodies that interfere with nerve function. Miller Fisher variant (MFv) is a subtype of GBS. We report a threefold surge of MFv and GBS cases in two downtown Los Angeles community teaching hospitals.

In 1916, Guillain, Barré, and Strohl first described Guillain-Barré syndrome (GBS) as an acute flaccid paralysis in which patients lacked deep tendon reflexes (DTRs) and possessed albuminocytological dissociation in the cerebrospinal fluid (CSF).1 In the 1950s, Miller Fisher noted a variant of GBS in which patients presented with a triad of ophthalmoplegia, ataxia, and areflexia.2 GBS has an incidence of 1-2 cases per 100 000 person-years worldwide and increases with age—after 10 years old, there is a 20% increase in incidence with every decade of life.3,4 Miller Fisher variant (MFv) has an incidence of 1-2 cases per 1 000 000 person-years.5 MFv is extremely rare and only occurs in approximately 5% of GBS cases in the United States.1 However, in Japan, MFv is reported to be present in over 25% of GBS cases.6 Clearly, there are some environmental, geographic, and possible genetic factors that may affect the incidence of GBS and its variants.

Guillain-Barré syndrome (GBS) is typically preceded by an inciting respiratory or gastrointestinal infection. Oftentimes, these illnesses are mild and underreported by patients. Over 90% of GBS cases are associated with an infection, and the usual suspects include Campylobacter jejuni, Mycoplasma pneumonia, Haemophilus influenza, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Enterovirus infections.5 Other reported triggers of GBS include pregnancy, psychological stress, and H1N1 influenza vaccination.3,5,7 MFv, like GBS and other acute autoimmune neuropathies, occurs when antibodies initially produced to target a pathogenic invader cross-reacts with structurally similar self-proteins.8 In the case of GBS and its variants, the proteins of peripheral nerves are damaged in the immunological crossfire resulting in varying patterns of neuropathy.6,8

Diagnosis of GBS and MFv is based on clinical findings, but can be supported by cerebrospinal fluid (CSF) analysis, electrodiagnostic studies, and ganglioside antibody testing.
Commonly tested antibodies include, but are not limited to, GM1, GM1b, GD1a, GD1b, GT1a, GT1b, and GQ1a. The particular antecedent infectious microorganism has been known to be associated with specific ganglioside antibodies—each with their own mechanism of action. Given its immunological basis, GBS and its variants are treated with intravenous immunoglobulin (IVIG) and plasma exchange. Both treatments are equally effective, and decision is based on availability and side effect tolerance.

2 | MATERIALS AND METHODS

Downtown Los Angeles (DTLA) is served by four community hospitals—two of which are Adventist Health White Memorial (AHWM) and California Hospital Medical Center (CHMC). AHWM is a 300 bed hospital, while CHMC is a class 2 trauma center with 310 beds. Both are community teaching hospitals with Joint Commission certified Primary Stroke Centers. The inpatient neurologic consultation services are provided by the same neurology medical group, thus giving the authors unique firsthand observation and diagnostic experience in all cases recorded. In the years before and after 2015, each hospital will see an average of four cases of GBS per year. In the middle of 2015, the authors had recognized a surge in the number of cases in GBS and MFv. Special efforts were initiated to include and record all cases. After 2015, the authors performed a retrospective chart review based on discharge diagnosis. A second round chart review did not capture any new cases that the authors did not already have on file. After the proper consents and IRB approval were obtained, patient data were conglomerated and analyzed. Testing of Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b antibodies was performed by ARUP laboratories using semiquantitative enzyme-linked immunosorbent assays.

3 | RESULTS

3.1 | Clinical profiles

In 2015, a total of 17 patients were diagnosed with GBS and MFv in Adventist Health White Memorial (AHWM) and California Hospital Medical Center (CHMC): eight patients with MFv and nine patients with GBS. 47% of cases were MFv, and 53% of cases were classic GBS. Ages ranged from 23 to 67 years with the average age being approximately 46 years for the total patient group and the individual GBS and MFv groups. One patient in both of the GBS and MFv groups had reported receiving the seasonal flu shot. Only three patients (all within the GBS group) had reported a preceding illness (33%)—notably none of the patients in the MFv group recalled a preceding illness. 13/17 patients (76%) received IVIG, and 6/17 patients received plasma exchange treatment (35%). 3/17 patients received combination treatment of IVIG and plasma exchange (17%). 1/17 patients did not undergo any treatment (5%); notably, the patient was pregnant at the time of diagnosis. 3/17 patients required mechanical ventilation (17%), all of whom were in the GBS group.

3.2 | Seasonality and timing

A majority of the documented GBS cases occurred during winter and spring (January to June, 78%), and all GBS cases occurred between February and July (Table 1). Similarly, a majority of MFv cases occurred during winter and spring (January to June, 75%). However, MFv cases were also seen in September and December (Table 2). The range of GBS cases occurred over five months, whereas the range of MFv cases occurred over 12 months. Seasons are divided into three month segments (winter: January–March, spring: April–June, summer: July–September, autumn: October–December).

3.3 | Ganglioside antibody profiles

Specific statistics are detailed in Table 3. Notable findings include that 50% of MFv patients tested positive for GQ1b; but none of these MFv patients tested positive for GM1 and GM2 antibodies. While the antibody panel for MFv patients is predominantly GQ1b, GBS patients were more evenly distributed; testing positive for all of the following: GD1a, GD1b, GQ1b, AsialoGM1, GM1, and GM2 (Table 3).

3.4 | Electrodiagnostic studies

Results of the nerve conduction tests are also detailed in Table 4. Of the 17 documented patients with GBS and MFv, five of the patients had undergone nerve conduction studies (NCS). All tested patients exhibited absent H waves and abnormal F waves. All the classic GBS patients were of the demyelinating subtype—half of whom had spared sural sensory nerve action potential (SNAP), and one-quarter of whom had motor block present. The MFv patient that underwent NCS showed normal motor conduction with spared sural SNAP and no motor block.

4 | DISCUSSION

Guillain-Barré syndrome is a group of immune-mediated neuropathies, and MFv makes up a small portion of its presenting variants. As previously mentioned, GBS has an incidence of 1-2 cases per 100,000 person-years worldwide. Of these GBS cases, MFv comprises 5% of cases in the United
### TABLE 1  Classic Guillain-Barré Syndrome (GBS) cases

| Patient-age/sex | Month | Antecedent illness | Recent vaccination | Antibodies | Clinical features | Mech vent | Treatment |
|-----------------|-------|--------------------|--------------------|------------|------------------|----------|-----------|
| 1-48/M          | Feb   | Flu                | No                 | GD1a: 132  | Ascending Weakness, Mild Dysphagia, Mild Dysarthria, No Respiratory Difficulty EOM normal | No       | IVIG      |
|                 |       |                    |                    | GD1b: 109  |                  |          |           |
|                 |       |                    |                    | GQ1b: 238  |                  |          |           |
| 2-60/M          | Mar   | Unknown            | No                 | AsialoGM1: 322 | Ascending Weakness, No Dysphagia, No Dysarthria, No Respiratory Difficulty EOM normal | No       | IVIG      |
|                 |       |                    |                    | GD1b: 306  |                  |          |           |
| 3-53/M          | Mar   | No                 | No                 | GM1: 53    | Ascending Weakness, Bulbar Weakness, Respiratory Failure Some Ophthalmoplegia | Yes      | Plasma Exchange, then IVIG |
|                 |       |                    |                    | GQ1b: 60   |                  |          |           |
| 4-49/M          | Apr   | Diarrhea           | No                 | GD1a: 529  | Ascending Weakness, No Dysphagia, No Dysarthria, No Respiratory Difficulty EOM normal | No       | IVIG      |
|                 |       |                    |                    | GD1b: 168  |                  |          |           |
| 5-24/M          | Apr   | Diarrhea & URI     | Flu shot 6 wk prior | GD1a: 127  | Ascending Weakness, No Dysphagia, EOM normal | No       | IVIG      |
|                 |       |                    |                    |            |                  |          |           |
| 6-45/M          | May   | No                 | No                 | AsialoGM1: 496 | Ascending Weakness, Bulbar Weakness, Respiratory Failure Some Ophthalmoplegia | Yes      | Plasma Exchange, then IVIG |
|                 |       |                    |                    | GM1: 468,  |                  |          |           |
|                 |       |                    |                    | GD1b: 803  |                  |          |           |
| 7-65/M          | Jun   | No                 | No                 | GM1: 93    | Ascending Weakness, Mild Dysphagia, Mild Dysarthria, No Respiratory Difficulty, EOM normal | No       | Plasma Exchange |
|                 |       |                    |                    | GD1b: 164  |                  |          |           |
| 8-45/F          | Jul   | No                 | No                 | GM1: 67    | Ascending Weakness, No Dysphagia, No Dysarthria, No Respiratory Difficulty, EOM normal | No       | IVIG      |
|                 |       |                    |                    | GM2: 62    |                  |          |           |
| 9-32/F          | Jul   | No                 | No                 | GM2: 65    | Ascending Weakness, Bulbar Weakness, Respiratory Failure, Ophthalmoplegia | Yes      | Plasma Exchange, then IVIG |

**Note:** Summary of GBS cases seen at Adventist Health White Memorial (AHWM) and California Hospital Medical Center (CHMC) in 2015. Details of each case are detailed, including month of illness, presence of antecedent illness, recent vaccinations, ganglioside antibody panel, clinical features of illness, need for mechanical ventilation, and treatment received.
States and up to 25% of cases in Japan. In the years prior to 2015, two large community hospitals in Downtown Los Angeles only saw approximately five cases of GBS per year, in 2016, seven GBS cases, two of which were MFv (29%), in 2017, eight GBS cases, two of which were MFv (25%), and in 2018, six GBS cases, one of which was MFv (17%).

**Table 2** Miller Fisher Variant (MFv) cases

| Patient-age/sex | Month | Antecedent illness | Recent vaccination | Antibodies | Clinical features | Mech vent | Treatment |
|-----------------|-------|--------------------|-------------------|------------|-------------------|----------|-----------|
| 10-67/F         | Jan   | No                 | No                | GD1b: 146 GQ1b: 478 | Ophthalmoplegia, No Limb weakness, Mild Dysphagia, Mild Dysarthria, No Respiratory Difficulty | No       | IVIG |
| 11-29/F         | Feb   | No                 | No                | AsialoGM1: 63 | Pregnant, Mild Ophthalmoplegia, No Limb Weakness, No Dysphagia, Mild Dysarthria, No Respiratory Difficulty | No       | No treatment |
| 12-59/M         | Mar   | No                 | No                | GD1b: 373 | Ophthalmoplegia, Dysphagia, Dysarthria No Respiratory Difficulty, Mild Limb Weakness | No       | IVIG |
| 13-41/M         | Apr   | No                 | No                | GQ1b: 496 | Ophthalmoplegia, No Dysphagia, No Dysarthria, Lower Extremity Weakness, Relative Sparing of Upper Extremity, a GBS-MFv Overlap | No       | Plasma Exchange |
| 14-23/F         | May   | No                 | Yes               | GQ1b: 51 | Mild Ophthalmoplegia, No Limb Weakness, No Dysphagia, No Dysarthria, No Respiratory Difficulty | No       | IVIG |
| 15-53/M         | Jun   | No                 | No                | GQ1b: 68 | Ophthalmoplegia, Mod Bulbar Weakness Mild Limb Weakness Mild Ataxia, A GBS-MFv Overlap | No       | IVIG |
| 16-62/F         | Sept  | No                 | Yes (unknown date) | GD1a: 68 | Ophthalmoplegia, No Limb weakness, Mild Dysphagia, Mild Dysarthria, No Respiratory Difficulty | No       | IVIG |
| 17-38/F         | Dec   | No                 | No                | GD1a: 84 | Ophthalmoplegia, No Limb weakness, Mild Dysphagia, Mild Dysarthria, No Respiratory Difficulty Profound Lethargy, Positive MRI Brainstem Lesion Bickerstaff-MFv Overlap | No       | Plasma Exchange |

**Note:** Summary of MFv cases seen at Adventist Health White Memorial (AHWM) and California Hospital Medical Center (CHMC) in 2015. Details of each case are detailed, including month of illness, presence of antecedent illness, recent vaccinations, ganglioside antibody panel, clinical features of illness, need for mechanical ventilation, and treatment received.
TABLE 3  Ganglioside antibody results

| Antibody    | GBS total | MFv total | Total   |
|-------------|-----------|-----------|---------|
| GD1a        | 3 (33.3%) | 2 (25%)   | 5 (29.4%) |
| GD1b        | 5 (55.5%) | 2 (25%)   | 7 (41.2%) |
| GQ1b        | 2 (22.2%) | 4 (50%)   | 6 (35.3%) |
| AsialoGM1   | 2 (22.2%) | 1 (12.5%) | 3 (17.6%) |
| GM1         | 4 (44.4%) | 0         | 4 (23.5%) |
| GM2         | 2 (22.2%) | 0         | 2 (11.8%) |

Note: Summary of ganglioside antibody panel for 17 patients diagnosed with GBS and MFv in Adventist Health White Memorial (AHWM) and California Hospital Medical Center (CHMC) in 2015.

However, in 2015, there was greater than a threefold increase in GBS cases compared to years prior to 2015—with an unusually high number of MFv cases. Possible reasons for this dramatic increase in GBS cases may be an associated spike in gastrointestinal or upper respiratory infections, community stressors or natural disasters. However, no increases in associated infections were noted in the two community hospitals in 2015. Surges in GBS cases have been noted after large earthquakes in Japan, regional differences in exposure to infections, noninfectious stressors (eg, war), and H1N1 influenza vaccination.3,7,12,13 There is a 14% increased risk of GBS in the winter compared to the summer.14 Similarly, in our patients, 75% of our documented GBS cases occurred in winter and spring. The seasonality of GBS also offers a clue to the common triggers of the disease, with upper respiratory infections being more common in the winter months.14

In addition to the high number of GBS cases in the DTLA areas in 2015, it is also notable that a high proportion of the GBS cases were Miller Fisher variants (47%). In comparison, the percentage of MFv in the United States is 5% and is reportedly over 25% in Japan.6 This markedly high percentage of MFv cases in our patient population may be because MFv is otherwise underdiagnosed when symptoms are mild. All of our MFv patients were unable to recall a prodromal illness (Table 2). Interestingly, each specific antecedent illness is associated with different presentation of MFv. For example, H. influenza infections are associated with the presenting symptom of diplopia and more often result in “pure MFv”—triad of ophthalmoplegia, ataxia, and areflexia without any limb weakness,15 whereas C jejuni infections are associated with blurred vision without diplopia and “incomplete MFv.” Cytomegalovirus (CMV) infections are associated with more severe disability with half of cases overlapping with GBS and Bickerstaff encephalitis.15 Due to the anti-GQ1b antibody positivity, MFv is often presumed to be a homogenous disease entity; however, it is clear that there is variability in its presentation depending on the antecedent illness.

Gangliosides contain oligosaccharide head groups with multiple sialic acid residues. These lipids are found in high concentrations in ganglion cells and nerve endings. Gangliosides play many important roles in the proper function of nerve cells including cell adhesion, signal transduction, and receptor function.10 Each pathogenic microorganism is associated with a different set of ganglioside antibodies. This antibody tatten is dependent on which ganglioside is most biochemically similar to the pathogen’s lipopolysaccharides. Notably, GQ1b is associated with C jejuni infections and over 90% of MFv cases test positive for GQ1b IgG antibodies.10 Given the symptoms of ophthalmoplegia in MFv, it is no surprise that GQ1b ganglioside is found in high levels in the oculomotor, trochlear, and abducens nerves.16 In our MFv population, 50% of patient tested positive for GQ1b antibodies—however, antibody titers typically decrease rapidly with clinical improvement.10 It is possible that ganglioside antibody testing may have been delayed in our population, resulting in a lower percentage of GQ1b antibody positivity.

Guillain-Barré syndrome symptoms typically occur 8-10 days after antecedent illness, and nadir of symptoms occurs within 6 days of initial presentation. Symptoms improve and mostly self-resolve in 1-2 months.5 However, treating with IVIG and plasma exchange has been shown to decrease the median time until motor recovery and duration of mechanical ventilation.5,11 Other proposed treatment modalities include eculizumab, eye patching, or prism therapy.5 Plasma exchange works by removing the cross-reacting antibodies from circulation.17 Several proposed mechanisms of IVIG include inhibition of complement pathway, direct effects of remyelination, T-cell modulation, and anti-idiotype antibody production.17

5  | CONCLUSION

Guillain-Barré syndrome is a group of polyneuropathies that typically occurs after an antecedent illness that triggers the production of cross-reacting antibodies that interfere with
nerve function. Miller Fisher variant (MFv) is a subtype of GBS that presents with the classic triad of ophthalmoplegia, ataxia, and areflexia. The number of cases of GBS and MFv spiked threefold in downtown Los Angeles (DTLA) in 2015, with an unusually high proportion of MFv cases. Given this finding, it is plausible the MFv is regularly underdiagnosed when the accompanying neurological symptoms are mild. Further investigation into the health and community events of DTLA during the 2015 winter and spring season may yield more insight into the triggers of this disease. Additionally, further research into surges of other immune-mediated neuropathies occurring in 2015 in the DTLA area may also provide more clues to their mechanism and treatment. Previously documented triggers include gastrointestinal and upper respiratory infections, natural disasters, and psychological stressors (eg, war). Overall, these findings emphasize the seasonality of GBS and its variants and offer more data regarding the diseases’ relation to ganglioside antibodies. This paper offers clear documentation of the GBS and MFv cases that occurred in the DTLA area in 2015—as well as an unusual predilection for the Miller Fisher variant.

ACKNOWLEDGMENT
We would like to thank Dr Victoria Ho, Brain Wu, Julie Jang, and Anna Pham for their invaluable assistance with this project.

The aforementioned study involving human participants was reviewed and approved by the Institutional Review Board (IRB) of both Adventist Health White Memorial and California Hospital Medical Center. The patients provided their written informed consent to participate in this study.

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS
MY: drafted manuscript, analyzed data, and performed literature review of related topics. AL: had significant contributions in acquisition of data, revision of manuscript, and direct patient care involved in case. All authors read and approved the final manuscript.

ORCID
Michael C. Yang  https://orcid.org/0000-0003-3292-8578
Antonio Liu  https://orcid.org/0000-0002-1932-7308

REFERENCES
1. Wakerley BR, Uncini A, Yuki N. GBS Classification Group; GBS Classification Group. Guillain-Barré and Miller Fisher syndromes–new diagnostic classification [published correction appears in Nat Rev Neurol. 2014 Nov; 10(11):612]. Nat Rev Neurol. 2014;10(9):537-544.
2. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57-65.
3. Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis. 2013;57(2):197-204.
4. Gupta SK, Jha KK, Chaladi MD, Alashi LT. Miller Fisher syndrome. BMJ Case Rep. 2016;2016:bcr2016217085.
5. Al Othman B, Raabe J, Kini A, Lee AG. Update: the Miller Fisher variants of Guillain-Barré syndrome. Curr Opin Ophthalmol. 2019;30(6):462-466.
6. Mitsui Y, Kusunoki S, Arimura K, et al. A multicentre prospective study of Guillain-Barré syndrome in Japan: a focus on the incidence of subtypes. J Neurol Neurosurg Psychiatry. 2015;86(1):110-114.
7. Tsuboi H, Sugeno N, Tateyama M, et al. Retrospective analysis of Guillain-Barré syndrome and Fisher syndrome after the Great East Japan Earthquake. Brain Behav. 2014;4(4):595-597.
8. Teener JW. Miller Fisher’s syndrome. Semin Neurol. 2012;32(5):512-516.
9. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125(Pt 12):2591-2625.
10. Gorenjac M. Clinical and diagnostic role of ganglioside antibody testing. EJFCC. 2004;15(3):95-96.
11. Verboon C, Doets AY, Galassi G, et al. Current treatment practice of Guillain-Barré syndrome. Neurology. 2019;93(1):e59-e76.
12. Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866-2877.
13. Lanska DJ. Historical perspective: neurological advances from studies of war injuries and illnesses. Ann Neurol. 2009;66(4):444-459.
14. Webb AJ, Brain SA, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry. 2015;86(11):1196-1201.
15. Koga M, Kishi M, Fukusako T, Ikuta N, Kato M, Kanda T. Antecedent infections in Fisher syndrome: sources of variation in clinical characteristics. J Neurol. 2019;266(7):1655-1662.
16. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993;43(10):1911-1917.
17. Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropsychopharmacol. 2009;7(4):337-342.

How to cite this article: Yang MC, Liu A. Surge of Miller Fisher variant and Guillain-Barré syndrome in two downtown Los Angeles community teaching hospitals. Clin Case Rep. 2020;8:2245–2250. https://doi.org/10.1002/ccr3.3132